Glaukos Corporation (GKOS) Tops Q4 EPS by 8c

Glaukos Corporation (NYSE: GKOS) reported Q4 EPS of ($0.06), $0.08 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $65.8 million versus the consensus estimate of $62.22 million.

“Glaukos delivered another strong quarter to end a transformative 2019 that saw us significantly grow our global Glaucoma franchise, advance our market-expanding pipeline and execute on a number of business development growth initiatives, including the acquisition of Avedro,” said Thomas Burns, Glaukos president and chief executive officer. “We continue to build upon our strong foundation to become an ophthalmic leader capable of transforming the treatment of chronic eye diseases with novel therapies for the much needed benefit of physicians and their patients for years to come.”

For earnings history and earnings-related data on Glaukos Corporation (GKOS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c